This trial will test whether a new chemotherapy agent is effective and safe in treating brain metastases from triple negative breast cancer.
- Breast Cancer
- Metastatic Brain Tumors
2 Primary · 4 Secondary · Reporting Duration: 6 months
Awards & Highlights
1 Treatment Group
QBS72S 12 mg/m2 IV injection
1 of 1
40 Total Participants · 1 Treatment Group
Primary Treatment: QBS72S · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 0 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
How hazardous is QBS72S to human health?
"There is limited evidence suggesting QBS72S's safety, giving it a rating of 2. However, there are no findings to support the drug's efficacy yet." - Anonymous Online Contributor
How many participants are involved in the current clinical research?
"Yes, the information hosted on clinicaltrials.gov confirms that this medical trial is actively engaging patients; it was initially posted on August 16th 2022 and its most recent update took place October 13th of that same year. The study requires 35 participants to be sourced from a single site." - Anonymous Online Contributor
Are there any vacancies available for this clinical experiment?
"The clinical trial is currently open to applicants, as referenced on the official website. This study was initially posted in August of 2022 and underwent its most recent update earlier this month." - Anonymous Online Contributor